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Abstract 59 
Background: 60 
The onset of Leber hereditary optic neuropathy (LHON) is relatively rare in childhood. This study 61 
describes the clinical and molecular genetic features observed in this specific LHON subgroup. 62 
Methods: 63 
Our retrospective study consisted of a UK paediatric LHON cohort of 27 patients and 69 additional 64 
cases identified from a systematic review of the literature. Patients were included if visual loss 65 
occurred at the age of 12 years old or younger with a confirmed pathogenic mitochondrial DNA 66 
mutation: m.3460G>A, m.11778G>A, or m.14484T>C. 67 
Results: 68 
In the UK paediatric LHON cohort, 3 patterns of visual loss and progression were observed: (i) 69 
classical acute (17/27, 63%); (ii) slowly progressive (4/27, 15%); and (iii) insidious or subclinical (6/27, 70 
22%). Diagnostic delays of 3-15 years occurred in children with an insidious mode of onset. 71 
Spontaneous visual recovery was more common in patients carrying the m.3460G>A and 72 
m.14484T>C mutations compared with the m.11778G>A mutation. Based a meta-analysis of 67 73 
patients with available visual acuity data, 26 (39%) patients achieved a final best-corrected visual 74 
acuity (BCVA) ≥ 0.5 Snellen decimal in at least one eye, whereas 13 (19%) patients had a final BCVA < 75 
0.05 in their better seeing eye. 76 
Conclusion: 77 
Although childhood-onset LHON carries a relatively better visual prognosis, approximately 1 in 5 78 
patients will remain within the visual acuity criteria for legal blindness in the UK. The clinical 79 
presentation can be insidious and LHON should be considered in the differential diagnosis when 80 
faced with a child with unexplained subnormal vision and optic disc pallor. 81 
 82 
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Synopsis 85 
Childhood-onset Leber hereditary optic neuropathy (LHON) carries a relatively better visual 86 
prognosis. Patients can present atypically with an insidious/subclinical course and LHON should be 87 
considered in children with unexplained subnormal vision and optic disc pallor. 88 
 89 
Word count: 35 90 
91 
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 92 
Introduction 93 
Leber hereditary optic neuropathy (LHON) (OMIM 535000) is a mitochondrial disorder that 94 
classically presents with acute or subacute bilateral loss of central vision in young adult men.[1-3] 95 
About 90% of patients carry one of the three major disease causing LHON mitochondrial DNA 96 
(mtDNA) mutations (MTND1 m.3460G>A, MTND4 m.11778G>A and MTND6 m.14484T>C), all of 97 
which encode for critical complex I subunits of the mitochondrial respiratory chain.[4] The greater 98 
availability of molecular genetic testing has broadened the phenotypic spectrum  associated with 99 
LHON to include patients with more slowly progressive visual deterioration exceeding 6 months in 100 
duration, and those with an insidious/subclinical course characterised by the incidental discovery of 101 
subnormal vision and optic atrophy in the absence of overt visual symptoms.[1, 5] Although disease 102 
conversion can occur anywhere from the first to the eight decade of life, the peak age of onset of 103 
visual loss among LHON carriers is 20-30 years old.[1, 4] Childhood-onset disease is relatively rare 104 
and less than 10% of patients were 12 years old or younger at the time of diagnosis in previously 105 
published case series.[1, 6-10] Although there is limited data on this important patient subgroup, the 106 
phenotype seems distinct from classical adult-onset LHON with atypical patterns of vision loss and a 107 
better visual prognosis as reported in a previously published study of 18 patients with childhood-108 
onset LHON.[7] 109 
 The aim of our study was to describe the clinical and molecular genetic characteristics 110 
associated with childhood-onset LHON, in particular the disease course and visual prognosis to 111 
better inform genetic counselling. We retrieved data for all eligible LHON patients that were seen at 112 
three major diagnostic centres for inherited optic neuropathies in the United Kingdom (UK). This UK 113 
paediatric LHON cohort was then combined with additional cases identified from a systematic 114 
review of the literature to generate a comprehensive meta-analysis of childhood LHON. 115 
 116 
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Patients and Methods 117 
Study Population 118 
This is a retrospective observational study approved by the local ethics committee at Moorfields Eye 119 
Hospital and it conformed to the standards set by the Declaration of Helsinki. LHON patients with 120 
disease onset at the age of 12 years old or younger were identified from the clinical and genetic data 121 
bases of the three main national diagnostic centres for inherited optic neuropathies in the UK 122 
(London, Oxford and Newcastle upon Tyne). We only included patients who carried one of the three 123 
canonical pathogenic mtDNA mutations, i.e., m.3460G>Am m.11778G>A and m.14484T>C. 124 
Additional clinical information where relevant were sought from the original referring clinicians. Best 125 
corrected visual acuity (BCVA) at disease onset, at the nadir and at the last follow-up clinic visit were 126 
recorded. Patients were sub-classified into three groups based on the mode of onset and 127 
progression of visual loss: (i) acute, if visual acuity deteriorated rapidly reaching the nadir within 6 128 
months from disease onset; (ii) slowly progressive, if visual deterioration occurred over a period 129 
exceeding 6 months; and (iii) insidious or subclinical, if the patient was clinically asymptomatic at the 130 
time that a diagnosis of optic atrophy or subnormal vision was made, and there was no change in 131 
visual acuity during subsequent follow-ups.[1, 7] Spontaneous visual recovery was defined as an 132 
improvement of BCVA by two lines or more on the Early Treatment Diabetic Retinopathy Study 133 
(ETDRS) chart or from off-chart to on-chart visual acuity (0.05 Snellen decimal). A binocular visual 134 
acuity of at least 0.5 (6/12) is the minimum standard for driving in the UK 135 
(https://www.gov.uk/driving-eyesight-rules, accessed on 8 November 2016) and below 0.05 (3/60) is 136 
the legal definition of registrable blindness in the UK 137 
(https://www.gov.uk/government/publications/guidance-published-on-registering-a-vision-138 
impairment-as-a-disability, accessed on 8 November 2016).  139 
When available, spectral-domain optical coherence tomography (SD-OCT) data was retrieved 140 
from the database of the SpectralisTM (Heidelberg Engineering Ltd., Heidelberg, Germany) and Cirrus 141 
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HD-OCT 4000TM (Carl Zeiss Meditec, Inc., Dublin, CA, USA ) platforms, and compared with the 142 
normative data described elsewhere.[11, 12] 143 
 144 
Systematic Literature Review 145 
A comprehensive literature search was conducted using the search terms ͞LHON͟, ͞Leďer hereditary 146 
optiĐ Ŷeuropathy͟or ͞Leďer’s hereditary optiĐ Ŷeuropathy͟ and  ͞Đhild͟,  ͞Đhildhood͟, ͞paediatriĐ͟ 147 
or ͞paediatric͟ on PubMed (https://www.ncbi.nlm.nih.gov/pubmed/, accessed on 8 November 148 
2016). We also reviewed all the papers that included previously published publications on childhood 149 
LHON in their reference lists. A LHON patient was included in our meta-analysis only if there was 150 
confirmation of the m.3460G>A, m.11778G>A, or m.14484T>C mtDNA mutation, and disease onset 151 
was clearly stated as being before the age of 12 years old or younger. None of the patients included 152 
in the historical case series was present in the UK paediatric LHON cohort. Due to the retrospective 153 
nature of our systematic literature review, more detailed clinical information regarding visual acuity 154 
and disease progression was not available for 29 of the 69 eligible patients included in our historical 155 
case series. 156 
 157 
Statistical Analysis 158 
 159 
The Kruskal-Wallis test and Mann-Whitney U independent samples test were used for comparing the 160 
age at onset between the LHON genotypes and the distribution of retinal layer thickness in LHON 161 
and control eyes, respectively. The “pearŵaŶ’s raŶk ĐorrelatioŶ test was used to assess for the 162 
strength of dependence between BCVA and retinal layer thickness (IBM Statistical Package of Social 163 
Sciences (SPSS) 22 v100).  164 
 165 
Results  166 
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UK Paediatric LHON Cohort 167 
The UK paediatric LHON cohort included 27 patients who were 2 to 11 years old (mean = 6.9 years, 168 
standard deviation (SD) = 2.9 years) at the time of onset of visual loss or when subnormal visual 169 
acuity or optic disc pallor first became apparent (Table 1). Thirteen patients (48%) carried the 170 
m.11778G>A mutation, 7 patients (26%) the m.3460G>A mutation, and 7 patients (26%) the 171 
m.14484T>C mutation (Table 2). Patients 24-27 belonged to the same family and out of 5 affected 172 
family members, 4 of them developed visual loss before the age of 6 years old. There was a known 173 
family history of LHON in 19 probands (70%). The male:female ratio varied between 2.5 to 3.3 for 174 
the 3 primary LHON mtDNA mutations with an overall male:female ratio of 3.0. There was no 175 
statistically significant difference in the age of disease onset between the LHON genotypes (Kruskal-176 
Wallis test, p=0.831). 177 
The majority of patients (17/27, 63%) experienced acute or subacute visual loss with the 178 
nadir being reached within 6 months of first disease onset. This mode of presentation was the most 179 
common in children harbouring the m.3460G>A mutation (6/7, 86%). In 4 patients (15%), visual 180 
acuity deteriorated slowly over a period extending up to 2 years. Three patients in this subgroup 181 
carried the m.14484T>C mutation and one the m.11778G>A mutation. There was an unexpectedly 182 
large number of children (6/27, 22%) with insidious or subclinical vision loss in the UK paediatric 183 
LHON cohort. Subnormal vision or optic disc pallor were detected during the first 2 years of life (n=4) 184 
or after failing the preschool visual screening assessment (n=2), which is mandatory in the UK for all 185 
4-5 year olds (Table 1). None of these children demonstrated or were suspected of having impaired 186 
visual performance during their early years and no visual deterioration occurred on subsequent 187 
follow-up. Molecular genetic confirmation of LHON in this insidious/subclinical group was markedly 188 
delayed between 3 to 15 years due to the atypical presentation.  189 
The mean final BCVA in the whole group of patients with childhood-onset LHON was 0.39 190 
Snellen decimal (SD = 0.38, range = light perception – 1.2 Snellen decimal, median = 0.25) with a 191 
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mean disease duration of 18 years (SD = 16 years, range = 1 - 56 years, median = 16 years). BCVA 192 
was ≥ 0.5 in 20/54 (37%) eyes and 14/27 (52%Ϳ patieŶts had at least oŶe eye ǁith BCVA ≥ Ϭ.ϱ. 193 
Conversely, BCVA was < 0.05 in 11/54 (20%) eyes and 5/27 (19%) patients met the legal definition of 194 
blindness with a BCVA < 0.05 in their better seeing eye. The m.11778G>A mutation was associated 195 
with a worse visual outcome compared with the m.3460G>A and m.14484T>C mutations (Table 2, 196 
Figure 1). Ten (37%) patients had asymmetric final BCVA with a difference ≥ 2 lines on the ETDRS 197 
chart, and this was associated with: (i) asymmetric visual loss in the acute stage (n = 2); (ii) 198 
asymmetric visual recovery following an acute disease onset (n = 2); (iii) slowly progressive visual 199 
loss (n = 3); and (iv) an insidious/subclinical course (n = 3). Patient 26, who harboured the 200 
m.14484T>C mutation, presented with slowly progressive visual deterioration in only one eye. In 201 
patients presenting with acute LHON, spontaneous visual recovery occurred in 20/34 (59%) eyes and 202 
16 (80%) of the recovered eyes achieved a BCVA ≥ Ϭ.ϱ. The mean time to recovery was 29 months 203 
(SD = 18 months, range = 9 – 60 months) and there was no significant differences between mutation 204 
subgroups (m.3460G>A, mean = 28 months; m.11778G>A, mean = 27 months; m.14484T>C, mean = 205 
32 months; Kruskal-Wallis test, p=0.958). Visual outcome was bimodal in the acute LHON group with 206 
a BCVA ≥ Ϭ.ϱ iŶ ϭ7/ϯϰ ;ϱϬ%Ϳ eyes and < 0.05 in 10/34 (29%) eyes (Figure 2). The majority of eyes for 207 
patients classified as having slowly progressive (5/8, 63%) or insidious/subclinical (11/12, 82%) LHON 208 
had BCVA < 0.5. 209 
SD-OCT imaging of the optic nerve head was available for 26 eyes of 13 patients. There was a 210 
significant reduction in the average peripapillary retinal nerve fibre layer (RNFL) thickness ranging 211 
from 49.0% to 58.4% compared with control values. On subgroup analysis, there was no significant 212 
correlation between BCVA and peripapillary RNFL thickness in any of the individual quadrants (data 213 
not shown). Perifoveal volumetric retinal SD-OCT scans were available for 10 eyes of 5 patients. 214 
Retinal thickness was significantly reduced in the LHON group (mean ± SD = 295.5 ± 17.7 m) 215 
compared with normal controls (mean ± SD = 340.8 ± 13.3 m, Mann-Whitney U test p < 0.001). This 216 
was specifically due to marked thinning of the GCL-IPL complex in the LHON group (mean ± SD = 43.2 217 
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± 2.9 m) compared with normal controls (mean ± SD = 93.5 ± 7.8 m, Mann-Whitney U test p < 218 
0.001). There was a statistically significant correlation between BCVA and the remaining ganglion cell 219 
layer-inner plexiform layer (GCL-IPL) thickness (Spearman rho=-0.773, p=0.009, Supplementary 220 
Figure 1). 221 
 222 
Meta-Analysis of Childhood-Onset LHON 223 
Our systematic review of the literature identified 69 LHON patients with onset of vision loss at the 224 
age of 12 years old or younger (mean = 8.5 years, median = 8.0 years, range = 3 - 12 years) from 20 225 
original publications covering diverse populations: Australia, Brazil, Chile, China, Finland, France, 226 
Germany, Italy, Saudi Arabia, Switzerland, the UK, and the USA (Supplementary Table 227 
1).[Supplementary appendix] The m.11778G>A mutation accounted for 47/69 (69%) of all the 228 
included cases. Visual acuity data was available for 40 patients and overall, 18/79 (23%) eyes 229 
aĐhieǀed a BCVA ≥ Ϭ.ϱ ǁhereas 18/79 (23%) eyes achieved a BCVA < 0.05. We merged the UK 230 
paediatric and historical LHON cohorts to generate a meta-analysis of childhood-onset LHON 231 
(Supplementary Table 2, Supplementary Figure 2). The number of patients with a BCVA ≥ 0.5 in at 232 
least one eye was 26/67 (39%) whereas the number of patients with a BCVA < 0.05 in their better 233 
seeing eye was 13/67 (19%). 234 
 235 
Discussion 236 
LHON is a disease of young adults and due to its relative rarity, there is limited data on the clinical 237 
features and visual prognosis of childhood LHON. In this study, we first identified a UK paediatric 238 
LHON cohort consisting of 27 patients diagnosed before the age of 12 years old, which was then 239 
combined with a historical cohort of 69 eligible patients from 20 previously published reports 240 
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(Supplementary Appendix). These two cohorts had similar clinical and molecular genetics profile 241 
and we therefore combined the data to generate a meta-analysis for a more comprehensive 242 
comparison with classical adult-onset LHON.  243 
The distribution of the three major disease causing LHON mutations (m.3460G>A = 19%, 244 
m.11778G>A = 62.5%, and m.14484T>C = 19%) in the childhood cohort is comparable with 245 
previously reported adult LHON case series with the m.11778G>A mtDNA mutation being the most 246 
common genotype. As expected, there was a male preponderance, but the overall male:female ratio 247 
of 1.8 is less marked than the 4-5 fold increased risk of visual loss seen among adult male 248 
carriers.[13-14] The mechanisms contributing to this rather intriguing male bias are not fully 249 
understood and a number of secondary genetic, hormonal and environmental risk factors have been 250 
implicated.[15] Smoking and to a lesser extent heavy drinking are regarded as important 251 
environmental triggers, but these factors are unlikely to be aetiologically important in young 252 
children. Although this hypothesis needs to be formally verified, the less pronounced sex bias in 253 
childhood LHON could arise because it is more heavily genetically determined by nuclear modifiers, 254 
which contribute to an earlier age of onset, but that are less sex determined or influenced. The other 255 
phenotypic extreme would be late-onset adult cases over the age of 50 years old where 256 
environmental risk factors, in particular smoking, are thought to play a more prominent role in 257 
precipitating disease conversion.[16-17] A systematic genomic comparison of childhood LHON, 258 
classical acute cases in young adults and late-onset LHON could therefore prove the key to dissecting 259 
the complex genetic-environmental modulators that contribute to visual loss in different groups of 260 
susceptible carriers. 261 
The classical acute pattern of vision loss was the most common presentation in childhood 262 
LHON, but over one third of patients either had a slowly progressive onset or even more strikingly, a 263 
subclinical or insidious disease evolution. In a previous report of 14 children with LHON from Barboni 264 
and colleagues, the 6 patients classified as having a slowly progressive course achieved better final 265 
14 
 
visual acuities compared with the acute group.[7] In contrast with this finding, the 4 patients in the 266 
UK paediatric LHON cohort did not have a better prognosis, with the vision deteriorating in the 267 
majority of eyes to less than the driving standards, i.e., BCVA < 0.5. The insidious/subclinical LHON 268 
subgroup was observed with all 3 major disease causing mtDNA mutations and the defining 269 
observation was the significant delays in reaching a confirmed molecular diagnosis, which ranged 270 
from 3 to 15 years. Visually asymptomatic children in whom subnormal vision and optic atrophy, 271 
which can be subtle, are detected incidentally have been reported previously and the diagnostic 272 
challenges are likely to be multifactorial.[10, 18] Visual performance in this age group is not always 273 
impaired due to the inherent adaptive capacity of young children and importantly, they may not be 274 
able to communicate changes in their vision effectively to their parents or guardians. A lack of 275 
clinical awareness of LHON in young children is also likely to be relevant in explaining the diagnostic 276 
delays in this patient group. 277 
LHON has a major impact on quality of life and the majority of patients will remain within 278 
the criteria for legally blindness.[19]The observed overall rates of spontaneous visual recovery of 279 
37% for all eyes in the entire UK paediatric LHON cohort and of 59% for the eyes of patients with 280 
acute LHON, are in line with the corresponding values of 28% and 63% reported by Barboni and 281 
colleagues.[7] Adult-onset LHON patients harbouring the m.14484T>C mutation have the best visual 282 
prognosis with a partial visual recovery rate of 37-58% compared with 4-25% for the m.11778G>A 283 
mutation, and 22-25% for the m.3460G>A mutation.[6, 8, 20-22] The variations in the reported rates 284 
of spontaneous visual recovery reflect possible sampling bias depending on the cohort size and the 285 
different criteria used to define a visually significant change in visual acuity from the nadir.[3] In our 286 
study, the rates of spontaneous visual recovery were 57%, 23% and 43% for the m.3460G>A, 287 
m.11778G>A and m.14484T>C mutations, respectively. Children carrying the m.3460G>A mutation 288 
therefore seem to have a better visual prognosis, and the recovery rate observed with the 289 
m.11778G>A mutation is also higher, compared with the clinical impression in patients with adult-290 
onset LHON.[6, 21] Based on our meta-analysis of 67 patients for whom visual acuity data was 291 
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available, 39% of patients achieved a BCVA ≥ Ϭ.ϱ iŶ at least oŶe eye ǁhereas 19% of patients had a 292 
BCVA < 0.05 in their better seeing eye. A more favourable final visual outcome was observed for all 293 
three genotypes in our childhood-onset LHON cohort compared with previously published figures 294 
(m.3460G>A: 14% versus 55-96%; m.11778G>A: 45% versus 73-98%; and m.14484T>C mutation: 6% 295 
versus 30-50% of eyes achieving a BCVA < 0.1).[1, 6, 8, 20-21] Mitochondrial turnover is implicated in 296 
the pathogenesis of LHON, both mitochondrial biogenesis and mitophagy being increased in 297 
fibroblasts of LHON patients.[23-24] The known age-related decline in mitophagy, and hence 298 
presumably mitochondrial biogenesis, may underlie this difference from adult disease.[25] 299 
 In conclusion, childhood-onset LHON represents a distinct phenotypic subgroup 300 
characterised by a more varied clinical evolution and a more favourable visual prognosis compared 301 
with classical adult LHON. Importantly, children do not always develop acute or subacute visual 302 
symptoms and a high index of suspicion is required in children presenting with unexplained 303 
subnormal vision and optic disc pallor to avoid potentially long diagnostic delays.  304 
 305 
306 
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Table 1. Demographics and clinical features of patients included in the UK paediatric LHON cohort. 
 
Patient Mutation 
Family 
history 
f/m 
Age at 
onset (y) 
Mode of 
onset 
Disease progression 
Final BCVA 
Time from 
onset (y) RE LE 
1 11778 yes f 6 S Gradual visual deterioration over 2 years. 
0.17 0.02 47 
2 11778 yes f 8 A No recovery 
LP LP 56 
3 11778 yes f 9 A No recovery 
0.03 0.03 38 
4 11778 yes m 11 A Worst BCVA: HM BE. Recovery within 12 months from onset. 
0.76 0.50 1 
5 11778 no m 8 A No recovery 
CF CF 33 
6 11778 no m 3 I Subnormal vision since birth. 
0.17 0.50 52 
7 11778 no m 9 A Worst BCVA: 0.08 RE, 0.4 LE. Asymmetric. 
0.10 0.50 18 
8 11778 yes m 11 A No recovery 
0.07 0.10 2 
9 11778 no m 2 I 
Subnormal vision detected when 2 years old. LHON diagnosed at 
the age of 8 yrs. 
0.25 0.08 17 
10 11778 yes m 8 A No recovery 
CF CF 10 
11 11778 no m 10 A 
Worst BCVA: CF BE. Recovery within 24 months from onset. 
Asymmetric recovery. 
0.08 0.66 7 
12 11778 yes m 2 I 
Subnormal vision detected when 2 years old. LHON diagnosed at 
the age of 6 yrs with BCVA of 0.18 RE and 0.17 LE. Slow visual 
recovery until 10 yrs old. 
0.35 0.36 4 
13 11778 yes m 2 I 
Optic atrophy noted at the age of 2 years.  LHON diagnosed at 
the age of 17 years. 
0.40 0.10 15 
14 3460 yes f 7 A Worst BCVA: 0.05 BE. Recovery within 4 yrs from onset. 
0.79 0.79 4.5 
20 
 
 
* From the same pedigree.   Best-corrected visual acuity (BCVA) recorded at last follow-up clinic visit in Snellen decimal. 
Abbreviations: A, acute; BCVA, best corrected visual acuity; BE, both eyes; CF, counting fingers at 0.25 metre; f, female; HM, hand movement; I, insidious; 
LE, left eye; m, male; RE, right eye; S, slowly progressive. 
 
15 3460 no f 11 A No recovery. 
CF CF 10 
16 3460 yes m 4 I Poor visual acuity noticed at pre-school screening assessment. 
0.17 0.17 16 
17 3460 no m 6 A Asymmetric visual recovery. 
0.67 0.25 18 
18 3460 yes m 8 A Worst BCVA: 0.05 BE. Recovery within 12 months from onset. 
1.20 1.20 1 
19 3460 yes m 10 A Worst BCVA: HM RE, CF LE. Recovery 
0.33 0.50 1.5 
20 3460 no m 5 A Worst BCVA: 0.1 BE. Recovery within 24 months from onset. 
1.00 1.00 2 
21 14484 yes f 9 S Gradual visual deterioration over 2 years. 
0.17 0.25 29 
22 14484 yes m 10 A Recovery within 9 months from onset. 
1.00 1.00 16 
23 14484 yes m 5 I Poor visual acuity noticed at pre-school screening assessment. 
0.25 0.25 39 
24* 14484 yes f 6 A Worst BCVA: 0.02 RE, 0.2 LE. Recovery within 5 yrs from onset. 
0.91 1.00 18 
25* 14484 yes m 6 S Asymmetric visual recovery. 
0.69 0.14 13 
26* 14484 yes m 4 S Slowly progressive visual deterioration in the left eye only. 
1.00 0.10 13 
27* 14484 yes m 5 A 
Off-chart vision (BE) at the nadir. Asymmetric recovery within 2-3 
yrs from onset. 
0.07 0.67 28 
21 
 
Table 2. Data summary of patients included in the UK paediatric LHON cohort. 
 
* Number of eyes with visual recovery. 
# Number of eyes with best-corrected visual acuity (BCVA) ≥ Ϭ.ϱ or < 0.05 in Snellen decimal.  
Abbreviations: BCVA, best corrected visual acuity; f, female; m, male. 
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n f m m:f 
Mean 
Median 
n (%) n (%) n (%) n (%) 
Mean 
Median 
n (%) n (%) 
11778 
13 
(13) 
3 10 3.3 
6.8 
8.0 
8 
(61) 
1 
(7) 
4 
(30) 
6 
(23) 
0.20 
0.10 
5/26 
(19) 
9/26 
(35) 
3460 
7 
(7) 
2 5 2.5 
7.3 
7.0 
6 
(86) 
0 
1 
(14) 
8 
(57) 
0.60 
0.73 
8/14 
(57) 
2/14 
(14) 
14484 
7 
(4) 
2 5 2.5 
6.4 
6.0 
3 
(29) 
3 
(29) 
1 
(14) 
6 
(43) 
0.54 
0.46 
7/14 
(50) 
0/14 
(0) 
All  
27 
(24) 
7 21 3.0 
6.9 
7.0 
17/27 
(63) 
4/27 
(15) 
6/27 
(22) 
20/54 
(37) 
0.39 
0.25 
20/54 
(37) 
11/54 
(20) 
